On June 27, 2019, Adaptimmune Therapeutics plc announced that Adrian Rawcliffe, currently Chief Financial Officer of the Company (CFO), will succeed James Noble as Chief Executive Officer (CEO), when Mr. Noble retires from his executive duties and transitions to a non-executive director role on the Company's Board, on September 1, 2019. Adrian Rawcliffe will join the Company's Board of Directors from the same date. The Company has started a global search for a new CFO, which will be the subject of a separate announcement.

Until a replacement is found, Mr. Rawcliffe will continue in his role as the Company's CFO, principal financial officer and principal accounting officer.